Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/10979

5,5-Diphenylhydantoin (phenytoin): Target Organs and Levels of Evidence for TR-404

Toxicology and Carcinogenesis Studies of 5,5-Diphenylhydantoin (Phenytoin) (CASRN 57-41-0) in F344/N Rats and B6C3F1 Mice (Feed Studies)

Chemical (Study Title)
CASRN		Peer Review DateRoute/Exposure LevelsStudy Laboratory
5,5-Diphenylhydantoin (phenytoin)
57-41-0		06/24/1992Dosed-Feed
R: 0,240,800,2400, MM: 0,30,100,300, FM: 0,60,200,600 PPM/50 PER GROUP		Battelle Columbus Laboratory

Levels of Evidence

Male Rats: Equivocal Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 0/50 1/50 4/50; CARCINOMA 0/50 1/50 0/50
Non-Neoplastic Lesions
  • LIVER: CENTRILOBULAR HYPERTROPHY
Other Considerations
  • LIVER: BASOPHILIC FOCUS 17/50 15/50 4/50
Female Rats: No Evidence
TypeOrgan/Tissue (Lesion)
Non-Neoplastic Lesions
  • LIVER: CENTRILOBULAR HYPERTROPHY
Other Considerations
  • LIVER: BASOPHILIC FOCUS 40/50 33/50 6/50
Male Mice: No Evidence
Female Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 5/48 13/49 22/50, HEPATOBLASTOMA OR CARCINOMA 0/48 1/49 12/50, COMBINED 5/48 14/49 30/50
Non-Neoplastic Lesions
  • LIVER: CENTRILOBULAR HYPERTROPHY